Skip to main content

Table 2 Comparison of CTCs, primary tumor, and metastatic tissue by HER2 status in patients with MBC

From: The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients

  Total CTC-HER2-negative CTC-HER2-positive
n (%) n (%)
PRIM-HER2 status (total) 107 70 (65 %) 37 (35 %)
 Negative 91 64 (70 %) 27 (30 %)
 Positive 16 6 (38 %) 10 (62 %)
MET-HER2 status (total) 46 36 (78 %) 10 (22 %)
 Negative 40 32 (80 %) 8 (20 %)
 Positive 6 4 (67 %) 2 (33 %)
  1. Overall accuracy of CTC-HER2 and PRIM-HER2 status: 69 %; overall accuracy of CTC-HER2 and MET-HER2 status: 74 %